NAFLD / MASLD Emerging Mechanism Research: What the Latest Science Reveals

NAFLD (nonalcoholic fatty liver disease) is the older name for what a 2023 multi-society consensus renamed MASLD (metabolic dysfunction-associated steatotic liver disease). The two terms describe the same underlying condition; MASLD diagnosis additionally requires at least one cardiometabolic risk factor, such as overweight, prediabetes or type 2 diabetes, hypertension, or dyslipidemia. Within this disease, MASH (metabolic dysfunction-associated steatohepatitis, formerly NASH) describes the inflamed, fibrosis-prone subtype. This article is about mechanism research, not about how to diagnose or dose treatment for an individual reader.

Across the primary mechanistic pathways described below, the practical takeaway is this: MASLD is not one disease process with one bottleneck, it is several converging processes, and a reader trying to understand their own risk or a family member's diagnosis should expect that no single test, gene, or drug target tells the whole story. Where a study reports a precise percentage or risk multiplier, treat that number as illustrative of a research finding rather than a fact to apply to an individual case, since exact figures depend on the population studied and can shift as larger studies replicate or refine them.

Why the field renamed NAFLD to MASLD

The 2023 nomenclature consensus, endorsed by AASLD, EASL, and other liver societies, replaced "nonalcoholic fatty liver disease" with "metabolic dysfunction-associated steatotic liver disease." The change was intended to anchor diagnosis to metabolic risk factors rather than to the absence of alcohol use, and to remove language many patients and clinicians considered stigmatizing. This is a naming and diagnostic-criteria change, not evidence that the underlying biology is newly understood; the mechanistic research summarized here predates and postdates the rename.

From a "two-hit" model to a multi-pathway model

Earlier research organized NAFLD around a two-hit hypothesis: fat accumulation in the liver (hit one) followed by a second insult such as oxidative stress or inflammatory injury (hit two) that converts simple steatosis into steatohepatitis. That framework struggled to explain patients who progressed rapidly without obvious oxidative markers, and patients who carried severe fat accumulation for years without progressing. The field has largely moved to a multi-parallel-hit model, in which genetic predisposition, gut-derived signals, lipotoxic fatty acids, insulin resistance, and innate immune activation are understood to operate simultaneously rather than sequentially. This shift matters clinically: it is a plausible explanation for why drugs targeting a single pathway repeatedly underperformed in phase 3 trials during the 2015-2022 period, though the multi-pathway model itself is an interpretive framework rather than a single proven fact.

Where the excess liver fat actually comes from

Hepatic fat in MASLD arrives from three sources: fatty acids released from body fat stores, dietary fat absorbed through the gut, and fat the liver manufactures on its own from excess carbohydrate, a process called de novo lipogenesis. Tracer studies in people with MASLD have found that de novo lipogenesis makes up a meaningfully larger share of liver fat than it does in people without the disease, though exact proportions vary by study population and should not be treated as fixed constants.

De novo lipogenesis is driven substantially by SREBP-1c, a transcription factor that both insulin and dietary fructose can activate. Fructose is thought to bypass a rate-limiting step in glucose metabolism, delivering carbon more directly toward fat synthesis, which is one biologically plausible mechanism connecting high fructose intake to liver fat, though it does not establish that fructose alone causes MASLD in a given person.

A separate contributor is impaired fat export. The liver normally packages excess fat into VLDL particles for release into the bloodstream. In MASLD, cellular stress in the endoplasmic reticulum is thought to impair the protein folding needed to assemble VLDL, trapping fat inside liver cells. Saturated fatty acids that accumulate as a result can trigger a cellular stress response that links simple fat accumulation to cell injury and inflammation.

Mitochondrial dysfunction: a fat-burning system that overcorrects, then fails

Healthy liver cells burn fatty acids through mitochondrial beta-oxidation. Research using biopsy and metabolic-tracing methods has described an early compensatory phase in MASLD, where mitochondria appear to work harder to clear excess fat, followed by a later phase in simple steatohepatitis where oxidative capacity appears to decline. The proposed mechanism is that early hyperactivity generates excess reactive oxygen species that progressively damage mitochondrial DNA and the electron transport chain, eventually reducing the liver's capacity to burn fat at all. This sequence is a mechanistic hypothesis supported by human and animal studies rather than a universally confirmed clinical stage marker, and it should be treated as plausible rather than fully established for any individual patient.

More recent mechanistic work has looked at regulated forms of cell death and stress-signaling pathways that connect mitochondrial injury to liver damage. A 2024 mechanistic review describes PANoptosis, a form of programmed cell death that combines features of pyroptosis, apoptosis, and necroptosis, as a candidate pathway linking hepatocyte injury to the inflammatory cascade seen in MASLD (Wang et al., 2024). Separately, AMPK, a cellular energy sensor that normally promotes fat oxidation and suppresses fat synthesis, has become a target of interest for hepatic fibrosis specifically, with a 2025 review summarizing preclinical evidence that restoring AMPK activity may reduce fibrogenic signaling in MASLD models (Zhang et al., 2025). Both lines of research remain at the preclinical or early-mechanistic stage; neither has yet produced an approved therapy built specifically on these targets, and translating rodent or cell-culture findings into human treatment effects is not guaranteed.

The gut-liver axis: how the intestine influences liver inflammation

A substantial body of research connects gut health to MASLD severity through what is often called the gut-liver axis. The proposed mechanism: intestinal barrier proteins such as claudin-1 and occludin become less effective in MASLD, allowing bacterial products, particularly lipopolysaccharide (LPS) from gram-negative bacteria, to reach the liver through the portal vein. Liver-resident immune cells (Kupffer cells) carry receptors that recognize LPS and respond by releasing inflammatory cytokines that can activate the cells responsible for scar formation.

A related line of evidence concerns gut bacteria's role in bile acid metabolism. Bacterial metabolism converts primary bile acids into secondary bile acids that activate FXR (farnesoid X receptor), a nuclear receptor that normally suppresses fat synthesis in the liver. Shifts in gut bacterial composition associated with MASLD have been linked to reduced secondary bile acid production and lower FXR activation, offering one explanation for why FXR-agonist drugs (such as obeticholic acid, studied in the REGENERATE trial) have shown some benefit for liver fibrosis. Short-chain fatty acids produced by beneficial gut bacteria, particularly butyrate, are also reduced in MASLD in several observational studies and are thought to normally support fat oxidation and dampen inflammatory signaling.

None of this establishes that a probiotic, diet change, or microbiome intervention reliably treats MASLD in humans; it establishes a biologically plausible connection that has motivated several drug and dietary research programs, most still at an early or mixed evidentiary stage.

Innate immunity, the NLRP3 inflammasome, and how fat becomes scar tissue

Liver inflammation in MASH appears to be driven primarily by the innate immune system, particularly Kupffer cells and recruited macrophages, rather than by T-cell-mediated immunity. Cholesterol crystals, saturated fatty acids, and molecules released from dying liver cells can activate a protein complex called the NLRP3 inflammasome, which triggers the release of IL-1beta, a cytokine capable of activating hepatic stellate cells. These stellate cells normally sit quietly in the liver storing vitamin A; once activated, they convert into collagen-producing cells that drive fibrosis. TGF-beta1, released by activated Kupffer cells and stressed hepatocytes, is considered the dominant fibrogenic signal in this process. Animal studies in which the NLRP3 pathway is genetically disabled show substantially reduced fibrosis despite similar fat accumulation, which supports treating inflammasome activation as a fibrosis-specific driver distinct from steatosis itself, though this distinction comes primarily from animal models rather than confirmed human intervention trials.

Genetic risk: PNPLA3, TM6SF2, and HSD17B13

Twin and family studies suggest genetics account for a meaningful share of MASLD susceptibility, and three variants are the most consistently replicated in the research literature.

PNPLA3 (rs738409). This gene encodes an enzyme involved in breaking down stored triglycerides in liver cells. A common variant reduces this enzyme's activity, and carriers show a well-documented, elevated risk of progressing to MASH and cirrhosis compared with non-carriers. This variant is more common in some Hispanic populations, which is one proposed contributor to disproportionate MASLD burden in those groups, though socioeconomic and dietary factors are also relevant and should not be discounted in favor of a purely genetic explanation.

TM6SF2 (rs58542926). This variant impairs VLDL secretion, trapping fat in the liver by a mechanism similar to the ER-stress pathway described above. Carriers appear to have a somewhat lower cardiovascular risk (because less VLDL-cholesterol circulates) alongside higher MASLD and cirrhosis risk, an example of a genetic trade-off between two disease risks rather than a uniformly "bad" variant.

HSD17B13. A splice variant in this gene appears protective, associated with reduced risk of progression to MASH and cirrhosis. It has become a target for RNA-interference drug development; early-phase trials of an investigational RNAi therapy targeting this gene have reported reductions in liver fat on imaging, though these results come from early-phase studies and require confirmation in larger, longer trials before they say anything about clinical outcomes such as fibrosis or cirrhosis prevention.

Resmetirom: mechanism-based development reaches an approved drug

Resmetirom (Rezdiffra, Madrigal Pharmaceuticals) received FDA approval in March 2024 as the first drug approved specifically for MASH with fibrosis (stages F2-F3), used alongside diet and exercise. This is an FDA-approved indication for a specific patient population defined by biopsy or non-invasive staging; it is not approved for simple fatty liver without fibrosis, and current approval status should be reconfirmed on fda.gov given the drug is still new to the market.

Its mechanism is a selective agonist of thyroid hormone receptor beta (THR-beta), the receptor subtype that predominates in the liver, as distinct from THR-alpha, which is more active in heart and bone tissue. This selectivity is the pharmacological rationale for why resmetirom is intended to accelerate hepatic fat oxidation and reduce fat synthesis without the cardiac and bone effects seen with older, non-selective thyroid hormone approaches.

The pivotal MAESTRO-NASH trial, a large randomized, placebo-controlled study, reported that resmetirom produced NASH resolution without worsening fibrosis in substantially more patients than placebo, along with reductions in LDL cholesterol and triglycerides consistent with a systemic metabolic effect. The precise percentages, confidence intervals, and secondary endpoints from this trial should be verified directly against the published trial report before being quoted to a patient, since exact figures matter for informed decision-making and this draft cannot independently confirm the numbers carried over from earlier drafts of this article.

Staging fibrosis without always needing a biopsy

Fibrosis stage, not the amount of fat itself, is the strongest known predictor of long-term liver-related mortality in MASLD. Biopsy remains the reference standard for confirming fibrosis stage, but it is invasive and impractical for population-level screening, which has driven development of non-invasive alternatives:

• FIB-4 index, calculated from age, AST, ALT, and platelet count, is recommended by AASLD guidance as a first-line screening tool; a low score is used to rule out advanced fibrosis with reasonable confidence, though it performs less well at identifying who does have advanced disease and is not a substitute for biopsy when the picture is ambiguous.
• MRI-PDFF quantifies liver fat content and is widely used as a trial endpoint for steatosis.
• MR elastography (MRE) measures liver stiffness and is used to estimate the likelihood of significant fibrosis, again as a screening and monitoring tool rather than a diagnostic replacement for biopsy in equivocal cases.

Other mechanism-based drug targets in development

Several other pathways described above are being pursued in ongoing trials as of mid-2025, though none has completed the level of confirmatory evidence resmetirom has:

• GLP-1 receptor agonists (such as semaglutide), already FDA-approved for type 2 diabetes and weight management, have shown NASH resolution benefits in earlier-phase MASLD trials, likely through weight loss, reduced fat release from adipose tissue, and possibly direct effects on liver immune cells. A phase 3 trial in MASH was ongoing as of this writing; readers should check current trial status before assuming a second MASH-specific approval exists.
• FGF21 analogs (such as pegbelfermin) aim to restore a hormone signal that is elevated but functionally resistant in MASLD, with early trials showing reductions in liver fat on imaging.
• ACC inhibitors (such as firsocostat) target the enzyme that controls the rate-limiting step of de novo lipogenesis, with early studies suggesting additive benefit when combined with an FXR agonist, consistent with the broader multi-pathway model.

Emerging basic-science work is also exploring newer regulatory layers of liver fat metabolism. A 2026 review, for example, summarizes preclinical evidence on circular RNAs (circRNAs) as regulators of hepatic lipid metabolism, a mechanistic area still confined to laboratory and early translational research rather than clinical application (Chen et al., 2026).

What is established, what is plausible, and what is not yet proven

Established: MASLD/NAFLD involves excess hepatic fat accumulation from adipose-derived fatty acids, dietary fat, and increased de novo lipogenesis; fibrosis stage predicts liver-related outcomes better than steatosis grade; PNPLA3, TM6SF2, and HSD17B13 variants are reproducibly associated with altered MASLD risk; resmetirom is FDA-approved for MASH with fibrosis based on a large randomized trial.

Plausible but not fully proven in humans: that gut-microbiome-targeted interventions (probiotics, FXR agonists beyond the specific approved indications, dietary fiber) meaningfully alter fibrosis outcomes at a population level; that the "compensatory mitochondrial hyperactivity followed by collapse" sequence applies predictably to an individual patient's disease stage; that AMPK-targeted or PANoptosis-targeted drugs will translate from animal models into effective human therapies.

Not established: that any single mechanism (lipid overload, mitochondrial failure, gut dysbiosis, or a specific gene variant) is either necessary or sufficient on its own to predict who will progress to cirrhosis; that genetic testing for PNPLA3 or TM6SF2 currently changes individual treatment decisions outside a research or specialist setting.

A reader framework: matching your risk profile to the right question to ask

This is not a treatment protocol and does not replace an evaluation by a clinician. It is a way to organize which mechanism-related question is most relevant to a given situation, so a conversation with a doctor can be more specific.

The exception worth flagging: a reader with normal FIB-4 and normal imaging can still have fibrosis missed by non-invasive tests, particularly at intermediate risk scores, so a persistently abnormal liver enzyme pattern or a strong clinical suspicion should prompt discussion of biopsy rather than reassurance from a screening score alone. Anyone with signs of decompensated liver disease, such as jaundice, confusion, abdominal swelling, or gastrointestinal bleeding, needs urgent medical evaluation rather than routine follow-up.